Counterpoint: Intraperitoneal Chemotherapy: An Investigational Treatment in Ovarian Cancer

Author:
Robert F. OzolsDepartment of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Search for other papers by Robert F. Ozols in
Current site
Google Scholar
PubMed
Close
 MD, PhD

Intraperitoneal (IP) chemotherapy in ovarian cancer has been studied since 1978. Numerous phase II trials have been performed, which have shown that higher levels can be obtained in the peritoneal cavity compared with systemic circulation after administration of cytoxic agents in a large volume via a semi-permanent catheter. Three randomized trials have been performed in patients with ovarian cancer comparing different IP regimens to standard therapy with intravenous agents. The last two trials from the Gynecologic Oncology Group (GOG) and the Southwest Oncology Group (SWOG) compared two different IP regimens versus standard therapy with intravenous cisplatin plus paclitaxel. Although an improvement in progression-free survival was reported for the IP regimens, they have been associated with unacceptable toxicity, and no IP regimen can be considered standard therapy. Maintenance therapy with IP cisplatin also failed to improve survival in patients who obtained complete remission after intravenous chemotherapy. The GOG is considering another phase III trial of IP therapy that will compare a carboplatin-based regimen versus standard therapy with intravenous paclitaxel plus carboplatin. Unless such a trial shows an improvement in clinical outcome, intravenous carboplatin plus paclitaxel remains the standard of care and IP chemotherapy should not be used outside of a clinical trial.

Correspondence: Robert F. Ozols, MD, PhD, Senior Vice President, Medical Science, 333 Cottman Avenue, Fox Chase Cancer Center, Philadelphia, PA 19111. E-mail: Robert.Ozols@fccc.edu
  • Collapse
  • Expand
  • 1

    Alberts DS, Markman M, Armstrong D et al.. Intraperitoneal therapy for stage III ovarian cancer: A therapy whose time has come! J Clin Oncol 2002;20:39443946.

    • Search Google Scholar
    • Export Citation
  • 2

    McGuire WP. Intraperitoneal therapy for ovarian cancer: A sacrifice bunt. J Clin Oncol 2001;19:10011007.

  • 3

    Ozols RF. Intraperitoneal therapy in ovarian cancer: Time's up. J Clin Oncol 1991;9:197199.

  • 4

    Markman M, Bundy BN, Alberts DS et al.. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group. Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:10011007.

    • Search Google Scholar
    • Export Citation
  • 5

    Armstrong DK, Bundy BN, Baergen R et al.. Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): A Gynecololgic Oncology Group trial (GOG 172) (Abstr #803). Proc Am Soc Clin Oncol 2002;21:201a.

    • Search Google Scholar
    • Export Citation
  • 6

    Alberts DS, Liu PY, Hannigan EV et al.. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:19501955.

    • Search Google Scholar
    • Export Citation
  • 7

    Dedrick RL, Myers CE, Bungay PM et al.. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62:111.

    • Search Google Scholar
    • Export Citation
  • 8

    Markman M. Intraperitoneal chemotherapy. Semin Oncol 1991;18:248254.

  • 9

    Markman M, Reichman B, Hakes T et al.. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer. Gynecologic Oncology 1993;50:100104.

    • Search Google Scholar
    • Export Citation
  • 10

    Walker JL, Armstrong D, Bundy BN et al.. Intraperitoneal catheter outcomes on GOG 172: Randomized trial of IV vs. IP chemotherapy in optimal ovarian cancer (Abstrt #20). 35th Annual Meeting Society of Gynecologic Oncologists 2004:84.

    • Search Google Scholar
    • Export Citation
  • 11

    Ozols RF, Bundy BN, Greer BE et al.. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2003;21:31943200.

    • Search Google Scholar
    • Export Citation
  • 12

    du Bois A, Luck H-J, Meier W et al.. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:13201330.

    • Search Google Scholar
    • Export Citation
  • 13

    Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987;5:756767.

  • 14

    McGuire WP, Hoskins WJ, Brady MF et al.. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 1995;13:15891599.

    • Search Google Scholar
    • Export Citation
  • 15

    Piccart MJ, Floquet A, Scarfone G et al.. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer 2003;13:196203.

    • Search Google Scholar
    • Export Citation
  • 16

    Fujiwara K, Sakuragi N, Suzuki S et al.. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: Results of long-term follow-up. Gynecol Oncol 2003;90:637643.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 98 23 2
PDF Downloads 88 32 2
EPUB Downloads 0 0 0